J2h Biotech
Clinical trials sponsored by J2h Biotech, explained in plain language.
-
New fatty liver pill takes first step in human trials
Disease control CompletedThis early-stage trial tested a new oral drug called J2H-1702 in 100 healthy men to see if it is safe and how the body processes it. The drug is being developed for non-alcoholic steatohepatitis (NASH), a serious fatty liver disease. Participants received either the drug or a pla…
Phase: PHASE1 • Sponsor: J2H Biotech • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
New NASH drug shows promise in early trial
Disease control CompletedThis study tested a new drug called J2H-1702 in 87 adults with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. The goal was to see if the drug is safe and if it can reduce liver fat and scarring after 12 weeks compared to a placebo. Participants were randomly…
Phase: PHASE2 • Sponsor: J2H Biotech • Aim: Disease control
Last updated May 27, 2026 12:03 UTC
-
New NASH drug candidate tested in healthy volunteers for first time
Knowledge-focused CompletedThis early-phase trial tested a single dose of J2H-1702 in 16 healthy women aged 19-45 to see if it is safe and how the body processes it. The study did not involve people with NASH (a liver disease) and was designed to gather basic safety and drug-level information. Results will…
Phase: PHASE1 • Sponsor: J2H Biotech • Aim: Knowledge-focused
Last updated Jun 10, 2026 13:27 UTC